Mechanism-driven diagnostics are replacing single-marker cancer testing
Translational oncology is moving beyond histopathology and isolated biomarkers toward diagnostic models that track tumour biology across several layers at once. In solid tumours, the central problem is no longer whether a cancer carries a mutation, but whether a test can capture the state of the disease: how it grows, evades immunity, seeds metastases, and responds to treatment. The review by Daniels, Page, and Wise argues that mechanistically grounded diagnostics are better suited to that task than reductionist assays built around one analyte at a time.
A single genomic readout can identify an alteration, yet still miss the biology that determines clinical behaviour. Tumours with similar mutation profiles can diverge in metastatic potential, immune escape, and therapeutic sensitivity because those traits are shaped by transcriptional programs, protein expression, microenvironmental signals, epigenetic regulation, and metabolic state. The practical consequence is straightforward: a test can be analytically elegant and still be clinically incomplete.
Why specimen choice now sits at the center of diagnostic design
The review places unusual emphasis on specimen awareness, and for good reason. A diagnostic platform is only as informative as the material it interrogates. Tissue, blood, and other minimally invasive specimens do not carry the same biological information, and they do not capture disease equally well across cancer types or clinical settings. Matching the specimen to the question becomes essential when the goal is not merely detection, but classification, prognosis, minimal residual disease assessment, or treatment selection.
Blood-based assays have obvious appeal because they can extend access to screening and longitudinal monitoring without repeated tissue biopsies. Cell-free DNA testing, methylation profiling, and fragmentomic analysis are especially attractive when tumour tissue is scarce or inaccessible. Yet these approaches depend on tumour shedding behavior, assay sensitivity, and the underlying biology of the disease. A low-shedding tumour may look molecularly quiet in plasma even when the cancer is active in tissue. In that setting, a negative liquid biopsy does not equal biological absence; it may simply reflect the wrong specimen for the disease phenotype.
A blood test cannot discover biology a tumour never sheds
Multi-omics reveals clinically relevant signals that single assays miss
The review surveys evidence showing that integrated genome and transcriptome analysis, proteogenomics, single-cell atlases, methylation-based cell-free DNA assays, metabolomics, and microbiome profiling can expose clinically relevant biology that one-dimensional tests leave hidden. Genomic alterations matter, but they do not fully explain tumour state. Transcriptomic and proteomic layers often better reflect active pathways, cellular plasticity, and functional tumor programs that shape clinical behavior.
That matters most in solid tumours, where the same cancer can contain multiple cellular subclones and microenvironmental niches. Single-cell approaches are especially useful here because they map heterogeneity directly rather than averaging it away. In practice, this may improve risk stratification and help explain why some cancers resist therapy despite apparently actionable alterations. A mechanistic diagnostic framework aims to move from “what mutation is present?” to “what is the tumour doing right now, and what vulnerability does that state create?”
Proteogenomic work is particularly relevant because protein abundance and post-translational regulation often determine phenotype more directly than DNA sequence alone. Metabolic profiling and microbiome analysis extend that logic further, since both can influence tumour progression and treatment response through immune modulation and cellular energetics. These methods remain uneven in maturity, but they reflect a common clinical principle: biology is layered, and the assay should be layered too.
Colorectal cancer illustrates the promise and the limits of integrated testing
Colorectal cancer provides a useful example of why specimen-aware diagnostics are needed. The disease spans a wide biological range, from early lesions suitable for screening to advanced metastatic disease requiring deep molecular characterization. No single platform is likely to handle all of those tasks with equal accuracy. Tissue remains important for definitive histology and local molecular assessment, while blood-based assays may be more practical for surveillance and MRD detection over time.
For colorectal cancer and other solid tumours, the central diagnostic challenge is not just sensitivity. It is representation. A platform must represent the biology of the primary lesion, possible metastatic clones, and the residual disease left after treatment. If the specimen does not capture the dominant mechanism of oncogenesis or progression, the test may generate information that is technically correct but clinically incomplete.
Pre-analytical noise and external validation still slow translation
The review is equally clear about the barriers. Pre-analytical variability remains a major obstacle, especially for assays that depend on small molecular signals. Sample handling, processing time, contamination, and assay standardization can all distort results before a test ever reaches the analytic phase. Clonal haematopoiesis can also confound blood-based genomic assays by introducing non-tumour variants into the signal.
External validation remains uneven across emerging platforms, and model systems do not always reproduce the complexity of human cancer. Generated models can help establish biological plausibility, but they do not guarantee clinical utility. The same is true for promising molecular signatures discovered in small cohorts or specialized centers. Without broad validation, reproducibility across settings, and evidence that a test changes management in a beneficial way, dimensionality alone does not justify adoption.
More layers do not automatically mean more clinical value
The next diagnostic standard will have to prove utility, not just complexity
The review frames the next phase of cancer diagnostics as a search for integrated models that are mechanistically grounded and specimen matched. The appeal is easy to understand: multi-layered testing can better reflect tumour complexity, improve detection across disease states, and support more precise therapeutic selection. Yet the bar for implementation remains high. Diagnostics must show that they improve care in routine practice, not just that they generate richer datasets.
For clinicians, the implication is immediate. A molecular report that does not align with the biology of the specimen, the tumour type, or the intended clinical use may offer limited value, even when it is sophisticated. Screening, diagnosis, MRD monitoring, and treatment selection are distinct problems and should not be forced into the same assay logic. A specimen-aware framework accepts that different clinical questions require different inputs, and that the best test is the one that faithfully reflects the biology at hand.
The most difficult unresolved issues are practical rather than theoretical: which combinations of analytes should be prioritized, which specimens should be paired with which tumour states, and how emerging platforms can be validated against outcomes that matter to patients. Until those questions are answered, integrated diagnostics will remain a promising concept under constant pressure to prove its clinical worth.